NCT03227107UnknownNot Applicable
IRF-1 Regulate Alveolar Macrophage Pyroptosis in Acute Lung Injury and of Which Will be Possible Mechanism
Xiangya Hospital of Central South University1 site in 1 country100 target enrollmentStarted: January 1, 2016Last updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Sponsor
- Enrollment
- 100
- Locations
- 1
- Primary Endpoint
- neutrophil extracellular traps, caspase-1,cytokines measurement
Study Overview
Brief Summary
- enrollment criteria and clinical data collection: follow the principles of medical ethics, the development of inclusion and exclusion criteria, select 90 cases of ARDS patients, in the active treatment at the same time, according to the Berlin standard severity of the disease divided into mild group, moderate Group and severe group, according to the prognosis during hospitalization is divided into survival group and death group. BALF specimens were collected on the day of admission to detect the levels of NETs and alveolar macrophages. The acute and chronic health status scoring system Ⅱ (APACHEⅡ) and Murray acute lung injury score, blood routine, creatinine, urea nitrogen, fasting blood glucose, Item, mean arterial pressure, arterial blood gas analysis, oxygenation index; record the patient's mechanical ventilation time and other data;
- Pearson linear correlation analysis of BALF in the content of NETs, alveolar macrophage coke death level was a positive correlation between the Spearman rank correlation analysis BALF in the NETs content and alveolar macrophage coke death level, APACHE Ⅱ, Murray score, creatinine, Urea nitrogen, fasting blood glucose and other indicators and ARDS severity was positively correlated;
- To analyze the prognostic factors of different prognostic factors, to evaluate the content of NETs in BALF, the level of alveolar macrophage coke, APACHEⅡ and Murray scores were analyzed by receiver operator characteristic curve (ROC curve) Short - term survival outcome prognostic value.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 18 Years to 75 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •ARDS patients diagnosis within 3 days
- •Over 18 years old but no more than 75 years old
Exclusion Criteria
- •Severe thoracic open trauma
- •Pulmonary embolism
- •Severe cardiovascular and cerebrovascular disease
- •Endocrine system diseases
- •Coagulation dysfunction
- •Liver and kidney failure
- •Malignant tumors
- •Cardiogenic pulmonary edema
Outcomes
Primary Outcomes
neutrophil extracellular traps, caspase-1,cytokines measurement
Time Frame: 4 years
Assessments with neutrophil extracellular traps be presented in ng/ml; Assessments with caspase-1 and cytokines be presented in pg/ml
Secondary Outcomes
No secondary outcomes reported
Investigators
panpinhua
vice director of department of respiratory
Xiangya Hospital of Central South University
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 1
Safety Study of a Recombinant Protein Vaccine to Treat Esophageal CancerEsophageal CancerNCT01003808ImmunoFrontier, Inc.25
Completed
Phase 1
Study to Determine Maximum Tolerated Dose of LErafAON Combined With Radiotherapy in Patients With Advanced MalignanciesNeoplasmsNCT00024648INSYS Therapeutics Inc25
Completed
Phase 2
A Study of the Immunogenicity and Safety of the 2007-2008 Influenza VaccineOrthomyxoviridae InfectionsInfluenzaNCT00491257Sanofi Pasteur, a Sanofi Company130
Completed
Phase 2
A Study of the Immunogenicity and Safety of the 2006-2007 Influenza VaccineOrthomyxoviridae InfectionsInfluenzaNCT00343681Sanofi Pasteur, a Sanofi Company120
Completed
Phase 1
Study to Determine and Compare Plasma and Intrapulmonary Pharmacokinetics of WCK 2349 in Healthy Adult Human SubjectsIntrapulmonary Pharmacokinetics of WCK 2349NCT02253342Wockhardt30